These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15580678)

  • 21. Spironolactone in patients with heart failure.
    Larkin RJ; Atlas SA; Donohue TJ
    N Engl J Med; 2000 Jan; 342(2):132-3; author reply 133-4. PubMed ID: 10636751
    [No Abstract]   [Full Text] [Related]  

  • 22. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure.
    Teive HA; Munhoz RP; Werneck LC
    Mov Disord; 2007 Aug; 22(11):1678-9. PubMed ID: 17534964
    [No Abstract]   [Full Text] [Related]  

  • 24. Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction.
    Pitt B
    Eur Heart J; 2009 Feb; 30(4):387-8. PubMed ID: 19190013
    [No Abstract]   [Full Text] [Related]  

  • 25. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    BMJ; 2003 Nov; 327(7424):1141-2. PubMed ID: 14615339
    [No Abstract]   [Full Text] [Related]  

  • 26. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J; Bułło B; Rutkowski B
    Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 28. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Spironolactone and potassium].
    Kjeldsen K
    Ugeskr Laeger; 2004 Nov; 166(48):4392; author reply 4392-3. PubMed ID: 15587639
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug safety in patients with heart failure.
    Juurlink DN; Hansten PD
    Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
    [No Abstract]   [Full Text] [Related]  

  • 32. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
    Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intolerance to spironolactone in refractory cardiac insufficiency. Probable changes in the aldosterone receptors. Study of 11 cases].
    Sänchez Torres G; Posadas C; Boyer JL; Guzmán Lara J; Serrano P
    Arch Inst Cardiol Mex; 1981; 51(3):233-40. PubMed ID: 6456707
    [No Abstract]   [Full Text] [Related]  

  • 36. Spironolactone and hyperkalaemia in patients with impaired renal failure.
    McGeown MG
    Lancet; 1987 Nov; 2(8569):1207. PubMed ID: 2890827
    [No Abstract]   [Full Text] [Related]  

  • 37. Spironolactone-associated aggravation of renal functional impairment.
    Neale TJ; Lynn KL; Bailey RR
    N Z Med J; 1976 Mar; 83(559):147-9. PubMed ID: 1064790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
    Radó JP; Marosi J; Takó J; Dévényi I
    Am Heart J; 1968 Sep; 76(3):393-8. PubMed ID: 4951338
    [No Abstract]   [Full Text] [Related]  

  • 39. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
    Fiebeler A; Luft FC
    Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
    [No Abstract]   [Full Text] [Related]  

  • 40. [Urea and spironolactone therapy].
    Schwarzbach W; Bunzl W
    Munch Med Wochenschr; 1973 Jan; 115(3):76-80. PubMed ID: 4739290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.